Unconfirmed Rumors Circulate that Phase III Results of Stimuvax Endpoint Results May Have Been Leaked

Unconfirmed rumors are circulating that positive Phase III results of Oncothyreon's Stimuvax meeting endpoints may have been leaked today. Oncothyreon is rallying in pre-market on unusual volume and an apparent lack of news, despite numerous rumors circulating regarding its cancer treatment candidate Stimuvax. At this point, these rumors are unconfirmed, and Benzinga has not been able to find confirmation of any news on Stimuvax whatsoever. Benzinga notes that Celsion, another company in the cancer treatment sector, rallied over 9% yesterday. Oncothyreon also rallied over 9% yesterday. At last check Oncothyreon was trading over 14% higher this morning in pre-market trading. Of note, on July 18th, SeekingAlpha posted an article referencing Oncothyreon. That article can be found

. Of further note,

claims that as of July 14th, "The current short interest as a percentage of the float for ONTY is a very large 16.2%. The short-sellers have been increasing their bets from the last reporting period by an extremely large amount of 104.7%, or by about 3.4 million shares. It would take the bears two days to cover all of their short bets at an average daily volume rate of 3.1 million shares." A more recent update of the short interest from public sources shows over 22% short interest as of July 19th.